Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 17/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4252764 | 0.86 | ALDH1A1 (0.53) | MAPTKMT2ALMNAHPGD | |
| SCHEMBL4257857 | 0.86 | NPBWR1 (0.45) | NPBWR1MAPTKMT2ALMNAHPGD | |
| SCHEMBL4251747 | 0.85 | NPBWR1 (0.39) | NPBWR1MAPTLMNA | |
| SCHEMBL4253480 | 0.83 | ALDH1A1 (0.40) | NPBWR1KMT2ALMNAHPGD | |
| SCHEMBL4260200 | 0.82 | NPBWR1 (0.48) | NPBWR1MAPTKMT2A | |
| SCHEMBL4256751 | 0.82 | ALDH1A1 (0.47) | NPBWR1KMT2A | |
| SCHEMBL4252839 | 0.80 | NPBWR1 (0.47) | NPBWR1MAPTKMT2AHPGD | |
| SCHEMBL4257569 | 0.78 | ALDH1A1 (0.51) | NPBWR1MAPTKMT2ALMNAHPGD | |
| SCHEMBL4255663 | 0.76 | KMT2A (0.54) | NPBWR1MAPTKMT2ALMNAHPGD | |
| SCHEMBL4260164 | 0.76 | CYP19A1 (0.48) | MAPTKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481537-B2 | Caspase inhibitors based of pyridazinone scaffold | LG LIFE SCIENCES LTD. (KR) | 2013-07-09 | — | — | US | disclosed |
| US-20090291959-A1 | CASPASE INHIBITORS BASED OF PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2009-11-26 | — | — | US | disclosed |
| EP-2046757-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG Life Sciences Ltd. (KR) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008016239-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291959-A1 | CASPASE INHIBITORS BASED OF PYRIDAZINONE SCAFFOLD | CASP1, CASP2, CASP5 | NPBWR1 4356/4885MAPT 1074/4885KMT2A 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.